The synthetic purine nucleoside Ribavirin
eukaryotic cells and after intracellular phosphorylation exhibits
virustatic activity against a broad spectrum of DNA
and RNA viruses.25 Several studies have been conducted to
evaluate ribavirin monotherapy in daily doses of 600-1,200
mg in the treatment of chronic hepatitis C.26-28 While all trials
consistently showed a decrease in aminotransferase levels,
no virologic end-of-treatment responses were observed.